Fidia S.p.A. (BIT:FDA)
Italy · Delayed Price · Currency is EUR | Market Cap | 1.79M |
| Revenue (ttm) | 21.13M |
| Net Income (ttm) | -2.19M |
| Shares Out | 14.90M |
| EPS (ttm) | -1.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 653,311 |
| Average Volume | 1,541,353 |
| Open | 0.1200 |
| Previous Close | 0.1220 |
| Day's Range | 0.1162 - 0.1243 |
| 52-Week Range | 0.1075 - 3.6200 |
| Beta | 0.03 |
| RSI | 39.78 |
| Earnings Date | Mar 13, 2026 |
About Fidia
Fidia S.p.A., together with its subsidiaries, designs, manufactures, and sells high speed milling systems, numerical controls, milling heads, and software systems. Its accessories comprise HMS, a device for measuring and compensating geometric error on continuous or indexed bi-rotary heads and roto-tilting tables; TMSC, a device to measure length and diameter of the tool, as well as to check the shape; K5 tracer, a solution to perform continuous scanning of 3D surfaces; pushbutton panels; XPower digital drives for axis and spindle movement; and... [Read more]
Financial Performance
In 2024, Fidia's revenue was 17.53 million, a decrease of -38.98% compared to the previous year's 28.74 million. Losses were -9.30 million, 611.4% more than in 2023.
Financial StatementsNews
uniQure Stock Jumps After Scheduling FDA Type A Meeting For AMT‑130 Approval Pathway
uniQure N.V. (NASDAQ:QURE) shares are popping on Friday after the company ... Full story available on Benzinga.com
Mesoblast Stock Rises On Strong Year‑Over‑Year Growth In Ryoncil Sales
Mesoblast Ltd (NASDAQ: MESO) shares are trading higher on Friday after the company reported strong year‑over‑year growth in December quarter sales of its flagship therapy, Ryoncil . Mesoblast stock i...
Camurus's NDA Resubmission For Oclaiz Gets Accepted By FDA
(RTTNews) - Camurus AB (CAMX.ST) has announced on Friday that the U.S. Food and Drug Administration has accepted to review their resubmission of New Drug Application for Oclaiz, an extended-release oc...
Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application
Aquestive Therapeutics Inc. (NASDAQ: AQST) stock is trading lower on Friday, with a session volume of 5.68 million compared to the average volume of 2.79 million, as per data from Benzinga Pro . Why ...
CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Friday. Shares of CG Oncology Inc (NASDAQ: CGON) rose sharply during Friday's session after the company announced an exp...
Insmed Maps Aggressive 2026 As Newly Approved Lung Disease Drug Gains Traction, Pipeline Advances
Insmed Inc (NASDAQ: INSM) on Friday outlined a commercial and clinical roadmap for 2026, highlighting strong momentum from its respiratory portfolio and a series of upcoming trial readouts and launch...
AQST Faces FDA Setback Regarding Anaphylm NDA
AQST Faces FDA Setback Regarding Anaphylm NDA
Here's Why Biotech ETFs Are Rallying Hard
Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.
KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug
KalVista Pharmaceuticals Inc . (NASDAQ: KALV) on Thursday reported early commercial momentum for its hereditary angioedema treatment EKTERLY, highlighting growing prescriber adoption, repeat prescrip...
uniQure (QURE) Surges on FDA Meeting for Gene Therapy Approval
uniQure (QURE) Surges on FDA Meeting for Gene Therapy Approval
UniQure Announces FDA Type A Meeting To Discuss BLA Data For Huntington's Gene Therapy
(RTTNews) - uniQure N.V. (QURE) today announced that a Type A meeting with the FDA has been scheduled to discuss the Biologics License Application (BLA) data package intended to support accelerated ap...
MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission
uniQure gains as FDA sets up meeting on gene therapy
uniQure (QURE) stock jumps after FDA schedules a Type A meeting to discuss a potential accelerated approval for its AMT-130 gene therapy. Read more here.
Aquestive Therapeutics (AQST) Shares Drop 48% After FDA Setback
Aquestive Therapeutics (AQST) Shares Drop 48% After FDA Setback
Weekly Buzz: ScinoPharm Gets FDA Nod; GNLX's Olvi-Vec Shows Promise; GLUE's MRT-8102 Advances
(RTTNews) - The biotech industry witnessed several key clinical trial data readouts across multiple therapeutic areas, including lung cancer, cardiovascular risk, Alzheimer's, and hepatitis.
Tempus AI Stock Surges 82.4% in a Year: What's Driving It?
TEM shares are up 82.4% in a year as Genomics revenues surge, Data & Services scale, FDA clearances and EBITDA turns positive.
Aquestive drops as FDA flags issues in Anaphylm marketing application
Aquestive Therapeutics (AQST) stock plunges as FDA flags deficiencies in the company's new drug application for its allergy therapy, Anaphylm. Read more here.
uniQure's (QURE) Gene Therapy for Huntington's Disease Advances with FDA Meeting
uniQure's (QURE) Gene Therapy for Huntington's Disease Advances with FDA Meeting
Kezar Life Sciences: FDA Division Grants Type C Meeting To Discuss Development Of Zetomipzomib
(RTTNews) - Kezar Life Sciences (KZR) said the FDA Division of Hepatology and Nutrition has granted the company a Type C meeting for the first quarter to discuss the development of zetomipzomib, a sel...
Kezar Life Sciences (KZR) to Discuss Zetomipzomib with FDA
Kezar Life Sciences (KZR) to Discuss Zetomipzomib with FDA
Crispr Pioneer Launches Startup to Make Tailored Gene-Editing Treatments
Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA regulatory pathway to commercialize treatments for rare diseases.
MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars
MoonLake says FDA may allow approval filing for ... Full story available on Benzinga.com
Nationwide Cheese Recall Carries Risk Of Death—Here's What To Know
The FDA upgraded Ambriola Pecorino Romano to a Class I recall for Listeria. Check Boar's Head and other grated cheese dates through 2026 in 20 states.
Vanda Pharmaceuticals (VNDA) Faces FDA Setback on HETLIOZ Application
Vanda Pharmaceuticals (VNDA) Faces FDA Setback on HETLIOZ Application
Revolution Medicines (RVMD) Gains FDA Breakthrough Status for Cancer Drug
Revolution Medicines (RVMD) Gains FDA Breakthrough Status for Cancer Drug